Beyfortus approved in China for the prevention of RSV disease in infants
First and only RSV preventive option authorised for use in China.AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.[1] Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season. Beyfortus is the first approved preventive option to protect against RSV in a broad infant population, including protecting those infants born healthy at term, or